The App Won’t Sit With You. But Your Doctor Will.
Perimenopausal women are turning to AI apps for guidance their clinicians are not providing. The AI empathy research would call this a success. The compassion framework calls it a failure.
A 49-year-old woman has not slept through the night in four months. Her concentration is gone. Her joints ache. She is having hot flashes every two hours. She has brought a list of symptoms to three appointments in the past year.
The first clinician told her this was normal.
The second ordered thyroid labs.
The third spent eight minutes with her and said they could discuss hormone therapy when her symptoms were more established.
She downloaded an app.
That story is not exceptional. It is the median experience of perimenopause care in the United States. And the AI empathy research, which finds that patients rate chatbot responses as more empathic than physician responses, finds its most politically uncomfortable confirmation in menopause care.
The chatbot is more empathic because the clinician has not been there at all.
The Compassion Deficit in Menopause Care
Empathy in a menopause appointment means the clinician hears that a patient’s quality of life is significantly impaired and acknowledges that this matters. Compassion means being moved to act on it: to take the symptom burden seriously, to know the evidence well enough to offer effective treatment, and to stay with the patient across the transition rather than managing the appointment efficiently and moving on.
The menopause transition affects 100 percent of women who live long enough. Vasomotor symptoms affect approximately 75 percent of women, with roughly 25 percent describing severe, life-disrupting symptoms.
Genitourinary syndrome of menopause affects the majority of postmenopausal women and is underreported, underdiagnosed, and undertreated at rates that would be considered a clinical crisis if the affected organ were anything other than the vagina.
The evidence on menopausal hormone therapy has been substantially clarified since the Women’s Health Initiative findings were misread and misreported in 2002.
For healthy women under 60 or within 10 years of menopause onset, the benefit-risk profile of hormone therapy is favorable for most women with significant symptoms. The clinician who is still reflexively withholding hormone therapy in 2025 without individualized risk assessment is not being cautious. She is being undertrained, and her patient is paying for it in years of disrupted sleep, impaired cognition, and reduced quality of life.
Free readers see above. Paid subscribers continue below.
